Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Intas Pharma May Offload 10 Percent to Raise Rs200 Crore From Market (India)

This article was originally published in PharmAsia News

Executive Summary

Intas Pharmaceuticals is reportedly considering an initial public offering (IPO) on the Indian market. Expected to be worth about 10 percent of the company, the IPO would be the biggest public offering by an Indian drug manufacturer on record. Intas is also one of the fastest growing companies on the market, expanding at a rate of 20 percent to 25 percent. Much of that growth is due to the company's solid pipeline. Currently, Intas boasts therapies in a number of areas including central nervous system, cardiovascular, diabetes, gastroentrology, urology, and pain relief. Although the mid-size company already has a presences in South-East Asia, Africa, the U.S., Europe, and Latin America, Intas' public offering could position it to be a leader in the domestic market. (Click here for more

You may also be interested in...

CV Sciences Reboots PlusCBD Brand While Counting On New Immunity Products During Flu Season

CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.

Finance Watch: Have Investors Reached IPO Fatigue?

Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.

Expediting The Expedited: How Rolling CMC Review Process Is Working For COVID-19 Vaccines

US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts